Supply-demand gap in SSTR-targeted PET tracer access reported in company materials.
Cancer diagnosis and treatment
Accessible
Accessible
nuclear medicine
for everyone
We develop radiopharmaceuticals for cancer diagnosis and treatment, designed for reliable production and wider patient access. Our lead programme, FETO, has completed Phase 2.
The problem
Patients are waiting for scans
SSTR-targeted PET tracers are in short supply. Limited production capacity and short shelf-lives delay essential imaging for people with neuroendocrine tumours, holding up treatment decisions and adding stress while they wait.
Our answer
A tracer built for reliable supply
FETO is made with fluorine-18, the most widely produced medical radionuclide, using cassette-enabled synthesis. It is designed to reach more hospitals, more reliably, so patients get timely scans.
Platform design intended to support higher production volume through 18F radiochemistry.
Potential distribution reach improvement versus shorter-lived alternatives.
Core Technology
Why fluorine-18 matters
Fluorine-18 enables broader distribution reach and efficient dose production compared with generator-based isotopes, supporting scalable clinical access and high-quality PET imaging.
01
Clinical Access
Across diverse health systems through scalable production design.
02
De-risked Biology
With clinically validated targets and translational evidence.
03
Repeatable Pipeline
Expansion across radionuclides and oncology indications.
04
Standardised Synthesis
Automation-ready synthesis supporting multi-site replication.
Lead Programme Spotlight
Phase 2 completed
NMX-001A (FETO)
Pioneering our platform with a clinically validated target. NMX-001A is an 18F-based SSTR-targeted PET imaging programme for neuroendocrine tumours and additional SSTR-positive cancers.
Target
Somatostatin receptor 2
Initial Focus
Neuroendocrine tumours
Value Proposition
Scalable radiopharmaceuticals with high-precision diagnostic and therapeutic applications
Full Name
[18F]FET-βAG-TOCA
Platform Engine
Built on a modular, click chemistry engine
The same design principles enable efficient pairing with diagnostic or therapeutic radionuclides. The goal is a practical engine for repeatable asset creation and clinical translation.
Modular Design
Targeting vector plus interchangeable radioactive module.
18F
Built for access, distribution reach, and dose scalability from day one.
211At
Astatine-211 for potential alpha-emitting targeted radionuclide therapy.
161Tb
Terbium-161 for potential next-generation targeted radionuclide therapy.
Partnering
Partner with us
Collaborating across the ecosystem
We actively partner with hospital radiopharmacies, clinical research sites, and pharma innovators to accelerate patient access.